Ignite Creation Date:
2025-12-24 @ 11:13 PM
Ignite Modification Date:
2026-02-21 @ 6:45 PM
Study NCT ID:
NCT02474069
Status:
COMPLETED
Last Update Posted:
2019-07-05
First Post:
2015-02-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Moderate to Severe Plaque-type Psoriasis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | skin condition | View |
| None | skin disease | View |
| None | itching condition | View |
| None | psoriasis vulgaris | View |
| None | relapsing psoriasis | View |
| None | remitting psoriasis | View |
| None | immune-mediated systemic disease | View |
| None | skin lesions, red skin lesions | View |
| None | scaly patches | View |
| None | papules, plaques | View |
| None | itching | View |
| None | auto-immune | View |
| None | plaque-type psoriasis | View |
| None | plaque | View |